
GlaxoSmithKline is readying to move its post-traumatics stress disorder candidate orvepitant into phase II trials, a move being supported by …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

